Table 2. Univariable Cox proportional hazard analysis of OS and DFS including number of DEGs.
| OS | DFS | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Variable(n) | Months (95% CI) | HR | 95% CI | p-Value | Months (95% CI) | HR | 95% CI | p-Value | DEG | |
| Gender | 36 | |||||||||
| Male (27) | 45 (41-48) | Ref | 29 (23-36) | Ref | ||||||
| Female (19) | 39 (31-45) | 1.7 | 0.7 - 4.3 | 0.3 | 17 (9-26) | 2.4 | 1.2 – 5.1 | 0.02 | ||
| ECOG | 0 | |||||||||
| 0 (34) | 45 (42-49) | Ref | 28 (22-35) | Ref | 22-35 | |||||
| 1-2 (12) | 33 (25-42) | 3.2 | 1.3 – 8.2 | 0.01 | 13 (5-21) | 2.7 | 1.2 – 6.0 | 0.01 | ||
| Recurrence | 0 | |||||||||
| No (17) | 49 (46-52) | Ref | NA | |||||||
| Yes (29) | 38 (33-43) | 6.0 | 1.4 – 26.1 | 0.02 | NA | NA | ||||
| CRS | 0 | |||||||||
| 0-2 (29) | 43 (39-47) | ref | Ref | |||||||
| 3-4 (9) | 33 (23-43) | 1.8 | 0.6 – 5.2 | 0.3 | 1.4 | 0.6 – 3.4 | 0.4 | |||
| NACT | 208 | |||||||||
| No (31) | 43 (39-47) | Ref | 25 (19-32) | Ref | ||||||
| Yes (15) | 40 (33-47) | 1.4 | 0.5 – 3.6 | 0.5 | 22 (12-33) | 1.2 | 0.6 – 2.6 | 0.6 | ||
| TP53 double hit | 34 | |||||||||
| wt (22) | 42 (37-47) | Ref | 22 (14-30) | Ref | ||||||
| mt + del (24) | 42 (37-47) | 0.9 | 0.4 – 2.3 | 0.9 | 26 (19-34) | 1.2 | 0.6 – 2.4 | 0.7 | ||
| SMAD4 | 22 | |||||||||
| wt (39) | 44 (40-47) | Ref | 26 (20-32) | Ref | ||||||
| mt (7) | 31 (21-42) | 3.3 | 1.2 – 9.5 | 0.02 | 17 (3-30) | 1.9 | 0.8 – 4.7 | 0.2 | ||
| NRAS | 44 | |||||||||
| wt (41) | 43 (39-46) | Ref | 24 (18-29) | Ref | ||||||
| mt (5) | 36 (20-52) | 1.3 | 0.3 – 5.8 | 0.7 | 30 (13-47) | 0.8 | 0.2 – 2.6 | 0.7 | ||
Values are given in means.
OS, overall survival; DFS, disease free survival; HR, hazard ratio; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; NACT, neoadjuvant chemotherapy; mt, mutated; wt, wild type; del, deletion of gene; DEG, differentially expressed genes; NA, not applicable. OS and DFS (months) are calculated by the Kaplan-Meier method, HR and p-values are derived from Cox proportional hazard regression analysis.